Salvage therapy of progressive and recurrent Hodgkin's disease: Results from a multicenter study of the pediatric DAL/GPOH-HD Study Group

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 6181-6189

  Schellong, Günther ^a   Dörffel, Wolfgang ^b   Claviez, Alexander ^b   Körholz, Dieter ^b   Mann, Georg ^b   Scheel Walter, Hans G ^b   Bökkerink, Jos P M ^b   Riepenhausen, Marianne ^b   Lüders, Heike ^b   Pötter, Richard ^b   Rühl, Ursula ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ABVD PROTOCOL; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; INFANT; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; INFANT; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; VINBLASTINE;

EID: 24944569351     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.930     Document Type: Article

References (40)

1. Canellos GP, Norwich A: Management of recurrent Hodgkin's disease, in Mauch PM, Armitage JO, Diehl V, et al (eds): Hodgkin's Disease. Philadelphia, PA, Lippincott, Williams & Wilkins, 1999, pp 507-519
2. Phillips JK, Spearing RL, Davies JM, et al: VIM-D salvage chemotherapy in Hodgkin's disease. Cancer Chemother Pharmacol 27:161-163, 1990
3. Fairey AF, Mead GM, Jones HW, et al: CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChIVPP chemotherapy. Ann Oncol 4:857-860, 1993
4. Smith MR, Khanuja PS, Al-Katib A, et al: Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease. Cancer 73:1264-1269, 1994
5. Brusamolino E, Orlandi E, Canevari A, et al: Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann Oncol 5:427-432, 1994
6. Canellos GP, Petroni GR, Barcos M, et al: Etoposide, vinblastine, and doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP. J Clin Oncol 13:2005-2011, 1995
7. Fermé C, Bastion Y, Lepage E, et al: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 6:543-549, 1995
8. Aparicio J, Segura A, Garcera S, et al: ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 10:593-595, 1999
9. Josting A, Rudolph C, Reiser M, et al: Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13:1628-1635, 2002
10. Colwill R, Crump M, Couture F, et al: Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 13:396-402, 1995
11. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002
12. Chopra R, McMillan AK, Linch DC, et al: The place of high-dose BEAM therapy and autologous bone-marrow transplantation in poor-risk Hodgkin's disease: A single-center eight-year study of 155 patients. Blood 81:1137-1145, 1993
13. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993
14. Schmitz N, Glass B, Dreger P, et al: High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol 66:251-256, 1993
15. Laurence ADJ, Goldstone AH: High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma. Semin Hematol 36:303-312, 1999
16. Akpek G, Ambinder RF, Piantadosi S, et al: Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 19:4314-4321, 2001
17. Williams CD, Goldstone AH, Pearce R, et al: Autologous bone-marrow transplantation for pediatric Hodgkin's disease: A case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 11:2243-2249, 1993
18. Baker KS, Gordon BG, Gross TG, et al: Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 17:825-831, 1999
19. Frankovich J, Donaldson SS, Lee Y, et al: High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: Atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 7:49-57, 2001
20. Claviez A, Klingebiel T, Beyer J, et al: Allogeneic peripheral blood stem cell transplantation following fludrabine-based conditioning in six children with advanced Hodgkin's disease. Ann Hematol 83:237-241, 2004
21. Donaldson SS, Hudson M, Oberlin O, et al: Pediatric Hodgkin's disease, in PM Mauch, JO Armitage, V Diehl, et al (eds): Hodgkin's Disease. Philadelphia, PA, Lippincott, Williams & Wilkins, 1999, pp 531-562
22. Balwierz W, Armata J, Moryl-Bujakowska A, et al: Results of retreatment of 36 children with Hodgkin's disease relapsed after initial MVPP chemotherapy and involved field irradiation: A report from the Polish Pediatric Leukemia/Lymphoma Study Group. Pediatr Rev Commun 6:153-159, 1992
23. Schellong G, Hörnig-Franz I: Salvage therapy results in childhood Hodgkin's disease, in AR Zander, B Barlogie, (eds): Autologous Bone Marrow Transplantation for Hodgkin's Lymphoma and Multiple Myeloma. Berlin/Heidelberg, Germany, Springer Verlag, 1993, pp8-10
24. Brämswig JH, Hörnig-Franz I, Riepenhausen M, et al: The challenge of pediatric Hodgkin's disease: Where is the balance between cure and long-term toxicity? A report of the West German multicenter studies DAL-HD-78, DAL-HD-82, and DAL-HD-85. Leuk Lymphoma 2:183-193, 1990
25. Schellong G: Treatment of children and adolescents with Hodgkin's disease: The experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 9:619-634, 1996
26. Schellong G, Hörnig-Franz I, Rath B, et al: Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study [in German]. Klin Padiatr 206:253-262, 1994
27. Schellong G, Pötter R, Brämswig JH, et al: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease. The German-Austrian multicenter trial DAL-HD-90. J Clin Oncol 17:3736-3744, 1999
28. Dörffel W, Lüders H, Rühl U, et al: Preliminary results of the multicenter trial GPOH-HD-95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 215:139-145, 2003
29. Bonadonna G, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastin, and imidazole caroxamide versus MOPP. Cancer 36:252-259, 1975
30. Santoro A, Viviani S, Valagussa P, et al: CCNU, etoposide, and prednimustine ICEP) in refractory Hodgkin's disease. Semin Oncol 13: 23-26, 1986
31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
33. Cox DR: Regression models and life tables. J Stat Soc B 34:187-220, 1972
34. Bennett MH, MacLennan KA, Easterling MJ, et al: The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: An analysis of 271 non-laparotomised cases. Clin Radiol 34:497-501, 1983
35. Josting A, Rueffer U, Franklin J, et al: Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood 96:1280-1286, 2000
36. Josting A, Franklin J, May M, et al: New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma Study Group. J Clin Oncol 20:221-230, 2002
37. Bhatia S, Yasui Y, Robinson LL, et al: Late Effects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 23:4386-4394, 2003
38. Schellong G, Riepenhausen M: Late effects after therapy of Hodgkin's disease: Update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 216:364-369, 2004
39. Stoneham S, Ashley S, Pinkerton R, et al: Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 26:740-745, 2004
40. Lieskovsky Y, Donaldson S, Mylin A, et al: High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: Results and prognostic indices. J Clin Oncol 22:4532-4540, 2004